7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Vestibulocochlear Nerve Diseases D000160 1 associated lipids
Acromegaly D000172 6 associated lipids
Actinobacillus Infections D000189 4 associated lipids
Actinomycosis D000196 2 associated lipids
Addison Disease D000224 3 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Angina, Unstable D000789 14 associated lipids
Angioid Streaks D000793 1 associated lipids
Ankylosis D000844 1 associated lipids
Aortic Diseases D001018 11 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Arthropathy, Neurogenic D001177 1 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Abedin M et al. Vascular calcification: mechanisms and clinical ramifications. 2004 Arterioscler. Thromb. Vasc. Biol. pmid:15155384
Vidal K et al. Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. 2004 Pediatr. Res. pmid:15155868
Xiao HL et al. Expression and identification of mutated osteoprotegerin in culture cells and larvae of silkworm. 2004 Acta Biochim. Biophys. Sin. (Shanghai) pmid:15156274
Saidenberg-Kermanac'h N et al. Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. 2004 J. Clin. Immunol. pmid:15163893
Pioletti DP and Kottelat A The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. 2004 Biomaterials pmid:15172492
Livshits G et al. Genetic influences on the circulating cytokines involved in osteoclastogenesis. 2004 J. Med. Genet. pmid:15173242
De Wilde A et al. A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets. 2004 J. Cell. Physiol. pmid:15174095
Dovio A et al. [Pathophysiological significance and clinical utility of circulating osteoprotegerin]. 2004 Jan-Mar Ann. Ital. Med. Int. pmid:15176704
Taranta A et al. Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. 2004 J. Bone Miner. Res. pmid:15176994
Coetzee M and Kruger MC Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment? 2004 South. Med. J. pmid:15180028
Melhus H Soluble RANKL and risk of nontraumatic fracture. 2004 JAMA pmid:15187049
Kazama JJ Osteoprotegerin and bone mineral metabolism in renal failure. 2004 Curr. Opin. Nephrol. Hypertens. pmid:15199291
Walsh NC and Gravallese EM Bone loss in inflammatory arthritis: mechanisms and treatment strategies. 2004 Curr Opin Rheumatol pmid:15201606
Stilgren LS et al. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2004 Bone pmid:15207766
Tsangari H et al. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. 2004 Bone pmid:15207775
Terpos E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. 2004 Leukemia pmid:15215875
Brändström H et al. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). 2004 Blood Press. pmid:15223723
Wilson SE et al. RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. 2004 Invest. Ophthalmol. Vis. Sci. pmid:15223796
Kang HS et al. Receptor activator of nuclear factor-kappaB is induced by a rottlerin-sensitive and p38 MAP kinase-dependent pathway during monocyte differentiation. 2004 Mol. Cells pmid:15232218
Bord S et al. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. 2004 Br. J. Haematol. pmid:15238146
Buxton EC et al. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). 2004 J. Clin. Endocrinol. Metab. pmid:15240611
Kochanowska I et al. Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle. 2004 Cell Tissue Bank pmid:15241009
Corso A et al. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. 2004 Leukemia pmid:15241438
Harada M et al. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis. 2004 Hum. Reprod. pmid:15242994
Matsuo K and Ray N Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. 2004 Keio J Med pmid:15247511
Mosheimer BA et al. Expression and function of RANK in human monocyte chemotaxis. 2004 Arthritis Rheum. pmid:15248232
Xu D et al. Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members. 2004 Biochem. J. pmid:15250821
De Leenheer E et al. Evidence of a role for RANKL in the development of myeloma bone disease. 2004 Curr Opin Pharmacol pmid:15251126
Jung K et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. 2004 Int. J. Cancer pmid:15252851
Varga F et al. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. 2004 Calcif. Tissue Int. pmid:15255076
Garlet GP et al. Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. 2004 J. Clin. Periodontol. pmid:15257746
Baumann B et al. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. 2004 Acta Orthop Scand pmid:15260421
Tomek S et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. 2004 Gynecol. Oncol. pmid:15262127
Miyashita T et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. 2004 Clin. Exp. Immunol. pmid:15270863
Nociti FH et al. Cementoblast gene expression is regulated by Porphyromonas gingivalis lipopolysaccharide partially via toll-like receptor-4/MD-2. 2004 J. Dent. Res. pmid:15271967
Hashimoto T et al. [Biochemical markers in bone metastasis]. 2004 Gan To Kagaku Ryoho pmid:15272580
Oh KW et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. 2004 Clin. Endocrinol. (Oxf) pmid:15272921
Doi S et al. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. 2004 Ther Apher Dial pmid:15274686
Hofbauer LC and Schoppet M Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. 2004 JAMA pmid:15280347
Kanatani M et al. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. 2004 J. Cell. Physiol. pmid:15281085
Farach-Carson MC et al. Integrating rapid responses to 1,25-dihydroxyvitamin D3 with transcriptional changes in osteoblasts: Ca2+ regulated pathways to the nucleus. 2004 Steroids pmid:15288767
Vanderborght A et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. 2004 J. Rheumatol. pmid:15290725
Soufi M et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. 2004 J. Clin. Endocrinol. Metab. pmid:15292302
Schoppet M et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. 2004 J. Clin. Endocrinol. Metab. pmid:15292354
Lossdörfer S et al. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. 2004 J Biomed Mater Res A pmid:15293309
Kahl KG et al. Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. 2005 Osteoporos Int pmid:15300363
Sato T et al. Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. 2004 Am. J. Hematol. pmid:15307108
Giuliani N et al. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). 2004 Exp. Hematol. pmid:15308315
Colucci S et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. 2004 Blood pmid:15308561
Kondo T et al. 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. 2004 J. Bone Miner. Res. pmid:15312241

Table of Content